Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.21.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash $ 1,909,947 $ 592,053
Accounts receivable, net 0 500
Grant receivable 0 224,879
Prepaid expenses 88,573 157,493
Total current assets 1,998,520 974,925
Property and equipment, net 123,329 128,605
Right to use assets 464,245 489,536
Other assets:    
Patents, net 12,269 12,564
Intellectual property, net 165,060 176,850
Deposits, long term 44,520 44,520
Total other assets 221,849 233,934
Total assets 2,807,943 1,827,000
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $763,411 and $686,068, respectively 2,759,324 2,490,158
Deferred revenue, short term 34,981 63,331
Deferred revenue-grant 28,350 65,560
Lease liability, short term 109,556 106,290
Notes payable 21,480 21,480
Notes payable, related parties 290,110 290,110
PPP loan, short term 0 15,445
Total current liabilities 3,243,801 3,052,374
Long term liabilities:    
PPP loan, long term 0 12,555
EIDL loan, long term 74,300 74,300
Royalty obligation, net of discount of $6,216,328 and $6,331,662, related parties 2,505,772 2,390,438
Lease liability, long term 406,576 435,405
Deferred revenue, long term 63,656 72,281
Total liabilities 6,294,105 6,037,353
Commitments and contingencies 0 0
Deficit:    
Preferred stock, no par value, 600,000 authorized 0 0
Common stock, $0.001 par value; 750,000,000 shares authorized, 6,614,457 and 5,463,444 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 6,614 5,463
Common stock subscribed 100,000 100,000
Additional paid in capital 62,773,436 60,466,333
Accumulated deficit (66,271,598) (64,688,311)
Total deficit attributable to BioCorRx, Inc. (3,369,932) (4,094,899)
Non-controlling interest (116,230) (115,454)
Total deficit (3,486,162) (4,210,353)
Total liabilities and deficit 2,807,943 1,827,000
Convertible Series A Preferred Stock [Member]    
Deficit:    
Preferred stock, no par value, 600,000 authorized 16,000 16,000
Convertible Series B Preferred Stock [Member]    
Deficit:    
Preferred stock, no par value, 600,000 authorized $ 5,616 $ 5,616